Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3727
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines.

    To find out more about Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
AB Science
Abbott
AC Immune
Access
Active Biotech
Adaptimmune
Advanced Life Sciences
Advantagene
Advaxis
AEgera
AEterna Zentaris
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alnylam
AlphaVax
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
Apogenix
ApopLogic Pharmaceuticals
Apotex
Ardea Biosciences
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
BioLineRx
Biomas
Bionovo
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chlorogen
Chroma Therapeutics
Cleveland BioLabs
CombinatoRx
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CritiTech
CSL
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
DeveloGen
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
FibroGen
Galectin Therapeutics
Galena Biopharma
Generex
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Gerolymatos
Geron
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Glycotope
GPC Biotech
Gradalis
Green Cross
Harbor BioSciences
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intracel
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Kalypsys
Keryx Biopharmaceuticals
Kyowa Hakko Kirin
Leo
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MBiotec
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novelix
Novogen
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Pharminox
Pierre Fabre
Piramal
Progenics Pharmaceuticals
ProMetic Life Sciences
Protgen
Protherics
QLT
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Rosetta Genomics
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Shionogi
Shire
Sigma-Tau
SRI International
SuperGen
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
United Biomedical
Vaccinex
ValiRx
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
Virionics
ViroMed
ViroTarg
VM Discovery
Xerion
Yakult Honsha
YM BioSciences
Zensun
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
ADXS11-001
AE-37
AEG-35156
aflibercept
AGS-003
AGS-1C4D4
alvocidib
AME-133
ANZ-207
APG-101
apricoxib
ARC-100
ARQ-197
AS-101
AS-1411
astuprotimut-r
Auto TAG vaccine
AVX-701
bardoxolone methyl
belagenpumatucel-L
belinostat
bevacizumab
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
brivudine
BV-NSCLC-001
BZL-101
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
CB-10-01
CDX-1307
celecoxib
cenersen
cetuximab
CG-201
cilengitide
cintredekin besudotox
cixutumumab
conatumumab
CPI-613
CreaVax-PC
CRLX-101
crolibulin
CV-9103
CV-9201
CVac
dalotuzumab
dasatinib
DCVax-prostate
dinaciclib
docetaxel
doxorubicin
dulanermin
E-75
E-7820
emepepimut-S
eniluracil
enzastaurin hydrochloride
erlotinib
everolimus
fosbretabulin tromethamine
ganitumab
gataparsen
gefitinib
GI-4000
GSK-1120212
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
HE-3235
Her-2/Neu peptides
Hi-8 MEL
HS-110
ibritumomab tiuxetan
icotinib hydrochloride
ICT-107
idronoxil
imatinib mesilate
imetelstat
imMucin
IMO-2055
IMP-321
interleukin-12
ipilimumab
irinotecan
irinotecan hydrochloride
ISA-P53-01
JX-594
kahalalide F
KD032
L19-IL2
lapatinib ditosylate
lestaurtinib
LipoVIL12
litronesib
lonaprisan
lumiliximab
mapatumumab
masitinib
MDX-1379
MetXia
MGN-1601
MKC-1
mocetinostat
motexafin gadolinium
MVA-BN Her-2 vaccine
nadroparin
navitoclax
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
olaparib
ON-01910
Oncohist
OncoVAX
Onyvax-105
OTS-102
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
retaspimycin
Reximmune-C
Rexin-G
rindopepimut
rintatolimod
romidepsin
RX-0201
S-488410
sagopilone
SCIB-1
seliciclib
selumetinib
siltuximab
sipuleucel-T
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Survivac
talminogene laherparepvec
tegafur + uracil
temsirolimus
terameprocol
TG-4010
thymalfasin
tigapotide triflutate
tigatuzumab
tipapkinogene sovacivec
tipifarnib
TL-32711
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
varlitinib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volasertib
volociximab
vosaroxin
VX-001
WX-671
XL-147
XL-647
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines.
    To find out more about Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Apoptosis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lung Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Colorectal Cancer, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Leukemia and Prostate Cancer and by the compound strategy of Antibodies. Learn More


Ovarian Cancer Drug Pipeline Update
BioSeeker Group have identified 357 companies plus partners who are today developing 438 drugs targeting ovarian cancer in development. across 307 different targets. In addition, there are 6 suspended drugs and another 124 drugs where development has been ceased. Learn More